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Association between genetic variants of the reelin (RELN) gene and the risk for developing Alzheimer's
disease (AD) was examined in a sample of 432 patients and 308 controls. Single marker and haplotype
analyses revealed that the strongly linked rs528528 and rs607755 polymorphisms are associated with
AD risk in a gender speciﬁc manner. Among men, but not in women the rs528528 T/T and rs607755 A/A
genotypes were signiﬁcantly associated with the susceptibility to AD.
& 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative
disease, the leading cause of dementia among elderly people.
Neuropathologically, AD is deﬁned by extensive neuronal loss and
the accumulation of intracellular neuroﬁbrillary tangles composed
of hyperphosphorylated tau protein and extracellular deposits of
amyloid-ß (Aβ) peptide in the brain (Selkoe, 2001). The complex
late-onset form of AD is most likely caused by multiple genetic and
environmental susceptibility factors. Inheritance of the Apolipo-
protein E (APOE; MIM# 107741) ε4 variant is a widely studied ge-
netic predisposing factor for developing AD (Mahley et al., 2006).
Reelin, an extracellular matrix glycoprotein, is encoded by the
RELN gene (MIM# 600514), which is a potentially relevant candi-
date gene for AD on account of its biological function and chro-
mosomal localization. RELN gene maps to 7q22, which is located
next to an AD linkage region on the long arm of chromosome 7
(Pericak-Vance et al., 2000; Hahs et al., 2006; Ertekin-Taner, 2007).
Reelin plays a crucial role in the migration and positioning of
neurons during brain development and has been linked to pro-
cesses of synaptic plasticity, learning and memory formation (Herz
and Chen, 2006; Lakatosova and Ostatnikova, 2012).
Despite its expected important role in neurodegeneration, ac-
cording to our knowledge so far only three studies have examined
genetic associations of RELN with AD, and one with AD-related
neuropathology (Seripa et al., 2008; Antoniades et al., 2011;rved.
ent of Psychiatry, 57 Kálvária
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plicate the previous reports on associations between RELN single
nucleotide polymorphisms (SNP) and AD in an independent
sample. We determined the allelic variation of RELN by using
5 markers (rs2299356, rs528528, rs607755, rs6943822 and
rs4298437) in a Hungarian sample of 432 patients and 308 con-
trols, with potential linkage disequilibrium (LD) between genetic
markers.2. Methods
The study included 432 patients with late-onset AD (74.976.7
years of age (mean7SD), 70.375.1 years of age at onset
(mean7SD), men 35.1%) and 308 elderly, cognitively healthy con-
trol individuals (74.277.1 years of age (mean7SD), men 34.4%),
both groups of Hungarian origin. A consensus clinical diagnosis of
late-onset AD was established according to the National Institute of
Neurological and Communicative Disorders and Stroke/Alzheimer's
Disease and Related Disorders Association (NINCDS/ADRDA) criteria
(McKhann et al., 1984). The minimum age at onset was 65 years. All
recruitment and protocols were conducted with written informed
consent and with the approval of the Ethics Committee of the
Hungarian Council on Science and Health (ETT-TUKEB).
Genotyping of blood-derived DNA samples was performed by
applying commercial TaqMan single-nucleotide polymorphism
assays (Applied Biosystems, Foster City, CA). The polymerase chain
reaction ampliﬁcation was conducted in single-plex reactions in
96-well plates with a total volume of 20 μl using the following
ampliﬁcation protocol: 95 °C for 10 min, and 40 cycles of 92 °C
for 15 s and 60 °C for 1 min. Fluorescence measurements wereELN gene: Gender speciﬁc association with Alzheimer’s disease.
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Table 2
Genotype and haplotype frequencies of the RELN rs2299356, rs528528 and
rs607755 polymorphisms in men.
Polymorphisms AD patients Controls Chi-square P value (corrected p
valuea)
rs2299356 7.159 0.028 (0.084)
A/A 41 (27.5%) 15 (14.0%)
A/G 71 (47.7%) 56 (52.4%)
G/G 37 (24.8%) 36 (33.6%)
rs528528 10.084 0.006 (0.018)
T/T 44 (29.5%) 15 (14.0%)
T/C 74 (49.7%) 57 (53.3%
C/C 31 (20.8%) 35 (32.7%)
rs607755 8.617 0.013 (0.039)
A/A 43 (28.9%) 15 (14.0%)
A/G 72 (48.3%) 57 (53.3%)
G/G 34 (22.8%) 35 (32.7%)
Haplotypesb
A–T–A 44.3% 31.2% 8.998 0.003 (0.024)
G–C–G 39.4% 50.9% 6.631 0.010 (0.080)
G–T–A 8.0% 7.5% 0.037 0.847
A–C–G 5.5% 6.6% 0.244 0.621
Á. Fehér et al. / Psychiatry Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎2performed using the CFX96 Touch Real-Time PCR Detection Sys-
tem (Bio-Rad Laboratories, Inc., Hercules, CA).
Categorical variables were studied applying Fisher exact and
Pearson χ2-tests. The mean age of the AD and control groups was
compared by using the t-test for independent samples. Multiple
logistic regression model was used to test for interaction between
the RELN and APOE polymorphisms (under both dominant and
additive models), and between the RELN polymorphisms and
gender. In the case of signiﬁcant genotype by gender interaction
effect (rs2299356, rs528528, rs607755), we also compared geno-
type distribution between AD patients and controls separately by
gender using Pearson's χ2-test. To exclude Type I errors, we carried
out Bonferroni's correction for multiple testing for 3 single-marker
and 8 haplotype comparisons.
Hardy-Weinberg equilibrium testing, LD calculations, and
haplotype analyses were conducted using Haploview 4.2 (Barrett
et al., 2005). Power analysis was performed using G*Power
3.0 software (Faul et al., 2007), and the effect size was determined
according to the method published by Cohen (1988). Based on the
calculated effect sizes in men, our study sample has 82% power at
the signiﬁcance level of 0.05 to detect differences in rs528528, and
75% to ﬁnd differences in rs607755 genotype frequencies between
AD and control groups (effect sizes: w¼0.198 for rs528528 and
w¼0.184 for rs607755).A–T–G 1.4% 1.4% 0.0 0.997
G–C–A 0.7% 1.0% 0.144 0.704
G–T–G 0.7% 0.5% 0.043 0.835
A–C–A n.d. 0.9% 2.425 0.119
AD: Alzheimer's disease, n.d.: not detected, RELN: reelin gene
a To exclude Type I errors, we carried out Bonferroni's correction for multiple
testing for 3 single-marker and 8 haplotype comparisons.
b Haplotypes of the RELN rs2299356, rs528528 and rs607755 polymorphisms.
Chi-squares and p values for comparisons of the haplotype frequencies were de-
termined by using the Haploview 4.2 program.3. Results
No statistically signiﬁcant differences were found between AD
and control groups in terms of gender distributions and mean age.
All observed genotype frequencies in both controls and cases
conform to Hardy–Weinberg equilibrium.
Genotype distributions of the different RELN polymorphisms did
not differ signiﬁcantly between AD and control groups (Table 1).
The APOE ε4 allele was signiﬁcantly over-represented in the AD
group as compared to the control group (AD: 27.9%; control: 11.4%;
po0.0001). None of the investigated RELN polymorphisms showedTable 1
Genotype frequencies of the investigated RELN polymorphisms in the overall populatio
Chromosomal localization Polymorphisms AD patient
7:103669375 rs2299356
A/A 107 (24.8%
A/G 214 (49.5%
G/G 111 (25.7%
7:103748638 rs528528
T/T 117 (27.1%)
T/C 213 (49.3%
C/C 102 (23.6%
7:103749507 rs607755
A/A 112 (25.9%
A/G 218 (48.2%
G/G 112 (25.9%
7:103958224 rs6943822
C/C 88 (20.4%)
C/T 207 (47.9%
T/T 137 (31.7%
7:103985430 rs4298437
C/C 190 (44.0%
C/T 190 (44.0%
T/T 52 (12.0%)
AD: Alzheimer's disease, RELN: reelin gene
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Psychiatry Research (2015), http://dx.doi.org/10.1016/j.psychres.2015epistasis with APOE ε4 allele on AD risk in the logistic regression
model (p40.05). However, a marginally signiﬁcant interaction ef-
fect was found between the rs2299356 polymorphism and gendern.
s Controls Chi-square P value
1.242 0.537
) 68 (22.1%)
) 151 (49.0%)
) 89 (28.9%)
3.087 0.214
70 (22.7%)
) 150 (48.7%
) 88 (28.6%)
1.206 0.547
) 72 (23.4%)
) 146 (47.4%)
) 90 (29.2%)
0.434 0.805
57 (18.5%)
) 153 (49.7%)
) 98 (31.8%)
0.623 0.732
) 127 (41.2%)
) 144 (46.8%)
37 (12.0%)
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the rs528528 polymorphism and gender (p¼0.048) and between
the rs607755 polymorphism and gender (p¼0.023) in the logistic
regression model.
Stratiﬁcation of the data according to gender revealed signiﬁcant
differences of the rs2299356, rs528528 and rs607755 genotype
distributions in men (Table 2), but not in women. The frequency of
the rs2299356 A/A genotype was signiﬁcantly higher in the AD than
in the control group among men (χ2¼7.159 (2) p¼0.028, corrected:
p¼0.084). Compared to the controls, the rs528528 T/T genotype
was signiﬁcantly over-represented in the AD group in men
(χ2¼10.084 (2) p¼0.006, corrected: p¼0.018). Regarding the
rs607755 polymorphism, the A/A genotype occurred with a sig-
niﬁcantly higher frequency in the AD than in the control population
among men (χ2¼8.617 (2) p¼0.013, corrected: p¼0.039).
Strong LD was observed between the rs528528 and rs607755
(D′¼0.952, r2¼0.873) and between the rs6943822 and rs4298437
polymorphisms (D′¼0.926, r2¼0.355); while moderate LD was
found between the rs2299356 and rs528528 (D′¼0.724, r2¼0.494)
and between the rs2299356 and rs607755 polymorphisms (D′¼
0.687, r2¼0.454). According to our data two haplotype blocks can
be detected: rs2299356-rs528528-rs607755 (block 1) and
rs6943822-rs4298437 (block 2).
Haplotype frequencies of these polymorphisms did not differ
signiﬁcantly between cases and controls (p40.05). Stratiﬁcation
of the data on the basis of gender resulted in signiﬁcant differ-
ences in block 1 haplotype distributions in men (Table 2), in
contrast with the results in women. The A–T–A haplotype of the
rs2299356-rs528528-rs607755 polymorphisms was more fre-
quent in the AD than in the control group in men (χ2¼6.661 (1)
p¼0.003; corrected p¼0.024), while the G–C–G haplotype had a
higher occurrence in the control group (χ2¼7.768 (1) p¼0.010,
corrected: p¼0.080).4. Discussion
In single marker case-control analysis no signiﬁcant correlation
between RELN polymorphisms and AD risk was found in the
overall sample, whereas signiﬁcant association of the rs2299356
A/A, rs528528 T/T and rs607755 A/A genotypes with AD was ob-
served in men, but not in women. After correction for multiple
testing, only the effect of the SNPs rs528528 and rs607755 re-
mained signiﬁcant. Since reelin competitively binds to the same
receptors as APOE (D'Arcangelo et al., 1999), a possible interaction
between RELN and APOE genes on AD risk was also hypothesized,
but no epistasis was found.
The RELN genotype distribution observed in our control sample
is similar to earlier reports on other Caucasian control populations
(Buﬁll et al., 2013; Seripa et al., 2008; Kramer et al., 2011). In a
Spanish case-control study rs2299356 polymorphismwas found to
be associated with AD and rs528528 with mild cognitive impair-
ment (Buﬁll et al., 2013). Our study did not conﬁrm these results in
the Hungarian population. Similar to our ﬁndings no effect of the
rs607755 polymorphism was detected in an Italian sample in the
entire cohort; however, an opposite pattern was found after stra-
tiﬁcation according to gender: G/G genotype was associated with
AD risk among females (Seripa et al., 2008).
A genome wide association study aimed to identify genetic
variants that distinguish non-demented elderly with a heavy
neuroﬁbrillary tangle burden from those with a low neuroﬁbrillary
tangle burden. In the RELN gene rs6943822 and rs4298437 were
found to be associated with this AD-related neuropathology
(Kramer et al., 2011). Based on these results, we assumed that
these polymorphisms can confer susceptibility to AD, but our
ﬁndings did not support this hypothesis. A possible reason is thatPlease cite this article as: Fehér, Á., et al., Genetic analysis of the R
Psychiatry Research (2015), http://dx.doi.org/10.1016/j.psychres.2015our control group can be heterogeneous regarding the absence or
presence and magnitude of neuroﬁbrillary tangles in spite of the
fact that they are cognitively healthy individuals.
In haplotype analysis no signiﬁcant association was found be-
tween RELN haplotypes and AD risk in the overall sample, but the
A–T–A haplotype frequency of block 1 (rs2299356-rs528528-
rs607755) was signiﬁcantly higher in the AD compared to the
control group among men. These results are consistent with the
single marker ﬁndings. The rs2299356 polymorphism did not have
a signiﬁcant effect in itself, but it is linked to rs528528 and
rs607755 which were signiﬁcantly correlated with AD.
In the present study single marker and haplotype assessments
led to the conclusion that the strongly linked RELN rs528528 and
rs607755 polymorphisms may be associated with AD risk in a
gender speciﬁc manner. The medium sample size of our study is
an important limitation, therefore our ﬁndings should be inter-
preted with caution until further replication.Acknowledgments
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